Feed GDTC
GD

CytoMed Therapeutics Limited GDTC · NASDAQ

$0.92 +0.00% (+$0.00)

Summary

23 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: $1.46M against $453.8K.
  • The price moves less than the market (beta 0.05).

What to watch

  • The company made a loss over the last 12 months.
  • Revenue fell by 4.4% a year over the last 3 years.
  • It passes only 2 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (SGD)

Diluted EPS (SGD)

Revenue fell by 4.4% a year over the last 3 years.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy